Examine This Report on SGC0946
123). It is noteworthy that GLS2 is tumorigenic in breast cancer124, and its expression could compensate for lack of Gls in MYC-induced mouse liver tumours40. This suggests that GLS2 could confer resistance to GLS1-precise inhibitors, such as the allosteric inhibitor BPTES or CB-839, and this resistance may very well be hypothetically averted by th